Critical Review: RegeneRx Biopharmaceuticals (RGRX) vs. Protagonist Therapeutics (PTGX)
RegeneRx Biopharmaceuticals (NASDAQ: PTGX) and Protagonist Therapeutics (NASDAQ:PTGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.
Insider and Institutional Ownership
0.1% of RegeneRx Biopharmaceuticals shares are held by institutional investors. Comparatively, 57.4% of Protagonist Therapeutics shares are held by institutional investors. 10.9% of RegeneRx Biopharmaceuticals shares are held by insiders. Comparatively, 13.8% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares RegeneRx Biopharmaceuticals and Protagonist Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Protagonist Therapeutics||$20.06 million||9.38||-$36.95 million||($2.09)||-4.24|
RegeneRx Biopharmaceuticals has higher earnings, but lower revenue than Protagonist Therapeutics.
This table compares RegeneRx Biopharmaceuticals and Protagonist Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and price targets for RegeneRx Biopharmaceuticals and Protagonist Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
RegeneRx Biopharmaceuticals presently has a consensus target price of $1.50, suggesting a potential upside of 689.47%. Protagonist Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 136.75%. Given RegeneRx Biopharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe RegeneRx Biopharmaceuticals is more favorable than Protagonist Therapeutics.
Risk & Volatility
RegeneRx Biopharmaceuticals has a beta of -1.88, meaning that its stock price is 288% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 3.18, meaning that its stock price is 218% more volatile than the S&P 500.
Protagonist Therapeutics beats RegeneRx Biopharmaceuticals on 7 of the 12 factors compared between the two stocks.
About RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4 (Tß4), for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It also evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis. It is also developing an oral peptide targeting a GI condition other than IBD. The company was founded in 2006 and is headquartered in Newark, California.
Receive News & Ratings for RegeneRx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.